Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)

BACKGROUND AND AIMS: AGATE‐I Part I previously reported high sustained virologic response rates in hepatitis C genotype 4 patients with cirrhosis, with 12 and 16 weeks' treatment with a combination of two direct‐acting antivirals, ombitasvir and paritaprevir (codosed with ritonavir), plus ribav...

Descripción completa

Detalles Bibliográficos
Autores principales: Asselah, Tarik, Alami, Negar Niki, Moreno, Christophe, Pol, Stanislas, Karatapanis, Stylianos, Gschwantler, Michael, Horsmans, Yves, Elefsiniotis, Ioannis, Larrey, Dominique, Ferrari, Carlo, Rizzetto, Mario, Orlandini, Alessandra, Calleja, Jose Luis, Bruno, Savino, Schnell, Gretja, Qaqish, Roula, Redman, Rebecca, Pilot‐Matias, Tami, Kopecky‐Bromberg, Sarah, Yu, Yao, Mobashery, Niloufar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427060/
https://www.ncbi.nlm.nih.gov/pubmed/30937389
http://dx.doi.org/10.1002/hsr2.92

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427060/
https://www.ncbi.nlm.nih.gov/pubmed/30937389
http://dx.doi.org/10.1002/hsr2.92

Ejemplares similares